CA2106105A1 - Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same - Google Patents

Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same

Info

Publication number
CA2106105A1
CA2106105A1 CA002106105A CA2106105A CA2106105A1 CA 2106105 A1 CA2106105 A1 CA 2106105A1 CA 002106105 A CA002106105 A CA 002106105A CA 2106105 A CA2106105 A CA 2106105A CA 2106105 A1 CA2106105 A1 CA 2106105A1
Authority
CA
Canada
Prior art keywords
same
nitric oxide
polymer
methods
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002106105A
Other languages
French (fr)
Other versions
CA2106105C (en
Inventor
Larry K. Keefer
Joseph A. Hrabie
Joseph E. Saavedra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority to CA002106105A priority Critical patent/CA2106105C/en
Publication of CA2106105A1 publication Critical patent/CA2106105A1/en
Application granted granted Critical
Publication of CA2106105C publication Critical patent/CA2106105C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/30—Introducing nitrogen atoms or nitrogen-containing groups
    • C08F8/32—Introducing nitrogen atoms or nitrogen-containing groups by reaction with amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F112/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring
    • C08F112/02—Monomers containing only one unsaturated aliphatic radical
    • C08F112/04—Monomers containing only one unsaturated aliphatic radical containing one ring
    • C08F112/14—Monomers containing only one unsaturated aliphatic radical containing one ring substituted by hetero atoms or groups containing heteroatoms
    • C08F112/16—Halogens
    • C08F112/18—Chlorine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A polymeric composition capable of releasing nitric oxide including a polymer and a nitric oxide-releasing N2O2- functional group bound to the polymer;
pharmaceutical compositions including the polymeric composition; and methods for treating biological disorders in which dosage with nitric oxide is beneficial. The compositions can be used as and/or incorporated into implants, injectables, condoms, prosthesis coatings, patches, and the like for use in a wide variety of medical applications.
CA002106105A 1993-09-14 1993-09-14 Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same Expired - Fee Related CA2106105C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002106105A CA2106105C (en) 1993-09-14 1993-09-14 Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002106105A CA2106105C (en) 1993-09-14 1993-09-14 Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same

Publications (2)

Publication Number Publication Date
CA2106105A1 true CA2106105A1 (en) 1995-03-15
CA2106105C CA2106105C (en) 2008-03-18

Family

ID=4152307

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002106105A Expired - Fee Related CA2106105C (en) 1993-09-14 1993-09-14 Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same

Country Status (1)

Country Link
CA (1) CA2106105C (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996015781A1 (en) * 1994-11-22 1996-05-30 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of nitric oxide-releasing agents for reducing metastasis risk
WO1996016645A1 (en) * 1994-11-25 1996-06-06 The Wellcome Foundation Limited Use of nitric oxide donors in medicine
EP0724436A1 (en) * 1993-09-17 1996-08-07 Brigham And Women's Hospital Use of nitric oxide-adducts to prevent thrombosis on artificial and vascular surfaces
WO1996032118A1 (en) * 1995-04-10 1996-10-17 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
JPH11503456A (en) * 1995-04-10 1999-03-26 アメリカ合衆国 Polysaccharide-bound nitric oxide-nucleophile adduct
US6174539B1 (en) 1993-09-17 2001-01-16 Nitromed, Inc. Localized use of nitric oxide adducts to prevent internal tissue damage
US6255277B1 (en) 1993-09-17 2001-07-03 Brigham And Women's Hospital Localized use of nitric oxide-adducts to prevent internal tissue damage
EP0914348B1 (en) * 1996-08-02 2002-06-12 Duke University Medical Center Polymers for delivering nitric oxide in vivo
EP1690532A1 (en) * 2005-02-11 2006-08-16 NOLabs AB Device for gastric treatment and manufacturing process for the same
WO2006084914A2 (en) * 2005-02-11 2006-08-17 Nolabs Ab Device for gastric treatment and manufacturing process for the same
CN106574005A (en) * 2014-08-14 2017-04-19 罗门哈斯公司 Polymer with releasable gas

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910316A (en) * 1992-08-24 1999-06-08 The United States Of America, As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
US6290981B1 (en) 1992-08-24 2001-09-18 The United States Of America As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
US6352709B1 (en) 1993-09-17 2002-03-05 Nitromed, Inc. Localized use of nitric oxide-adducts to prevent internal tissue damage
EP0724436A1 (en) * 1993-09-17 1996-08-07 Brigham And Women's Hospital Use of nitric oxide-adducts to prevent thrombosis on artificial and vascular surfaces
EP0724436A4 (en) * 1993-09-17 1999-09-01 Brigham & Womens Hospital Use of nitric oxide-adducts to prevent thrombosis on artificial and vascular surfaces
US6174539B1 (en) 1993-09-17 2001-01-16 Nitromed, Inc. Localized use of nitric oxide adducts to prevent internal tissue damage
US6255277B1 (en) 1993-09-17 2001-07-03 Brigham And Women's Hospital Localized use of nitric oxide-adducts to prevent internal tissue damage
US6471978B1 (en) 1993-09-17 2002-10-29 Brigham And Women's Hospital Localized use of nitric oxide-adducts to prevent internal tissue damage
EP1393723A2 (en) * 1993-09-17 2004-03-03 Brigham & Women's Hospital Use of nitric oxide-adducts to prevent thrombosis on artificial and vascular surfaces
EP1393723A3 (en) * 1993-09-17 2004-10-20 The Brigham And Women's Hospital, Inc. Use of nitric oxide-adducts to prevent thrombosis on artificial and vascular surfaces
WO1996015781A1 (en) * 1994-11-22 1996-05-30 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of nitric oxide-releasing agents for reducing metastasis risk
WO1996016645A1 (en) * 1994-11-25 1996-06-06 The Wellcome Foundation Limited Use of nitric oxide donors in medicine
JP2010111675A (en) * 1995-04-10 2010-05-20 Usa Government Polysaccharide-bound nitric oxide-nucleophile adduct
JPH11503456A (en) * 1995-04-10 1999-03-26 アメリカ合衆国 Polysaccharide-bound nitric oxide-nucleophile adduct
WO1996032118A1 (en) * 1995-04-10 1996-10-17 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
EP0914348B1 (en) * 1996-08-02 2002-06-12 Duke University Medical Center Polymers for delivering nitric oxide in vivo
WO2006084914A2 (en) * 2005-02-11 2006-08-17 Nolabs Ab Device for gastric treatment and manufacturing process for the same
WO2006084914A3 (en) * 2005-02-11 2006-11-16 Nolabs Ab Device for gastric treatment and manufacturing process for the same
EP1690532A1 (en) * 2005-02-11 2006-08-16 NOLabs AB Device for gastric treatment and manufacturing process for the same
CN106574005A (en) * 2014-08-14 2017-04-19 罗门哈斯公司 Polymer with releasable gas

Also Published As

Publication number Publication date
CA2106105C (en) 2008-03-18

Similar Documents

Publication Publication Date Title
CA2216696A1 (en) Polysaccharide-bound nitric oxide-nucleophile adducts
CA1087984A (en) Synthetic resin-base, antibiotic compositions containing amino acids
CA2131830A1 (en) Soft resilient interocclusal dental appliance, method of forming same and composite for same
CA2106105A1 (en) Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
CA2132293A1 (en) Medical devices subject to triggered disintegration
DE60220049D1 (en) PHARMACEUTICAL COMPOSITIONS CONTAIN A SOLID DISPERSION OF A MEDICAMENT IN THE WATER AND A SOLUBLE-STARTERING POLYMER
CA2158638A1 (en) A Composition and a Method for Tissue Augmentation
EP0627899A4 (en) Injectable ceramic compositions and methods for their preparation and use.
DE69432025D1 (en) DELAYED RELEASE FORMULATIONS FOR METOPROLOL DELIVERY OVER 24 HOURS
EP1234586A3 (en) Hepatoselective pharmaceutical actives
BR9710984A (en) Use of a polymer, homopolymer or copolymer in obtaining a medication to treat a gastrointestinal or microbial infection in a mammal
DE10114247A1 (en) Antibiotic / antibiotics-polymer combination
BR9814118A (en) New composition of matter
CA2128044A1 (en) Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
ZA921875B (en) New esters of bi- and tricyclic amino alcohols, their preparation and their use in pharmaceutical compositions
GB2197329B (en) Hard tissue substitute composition
PT93384A (en) Process for the preparation of a drug release coating material for prolonged-release acrylate formulations containing (meth) acrylate copolymers
CA2157323A1 (en) Gepirone dosage form
CA2143413A1 (en) Local Drug Delivery Film, for Periodontal Treatment
CA2067381A1 (en) Treatment of hiv infections and compounds useful therein
CA2159730A1 (en) Ionene polymers as anthelmintics in animals
CA2189436A1 (en) Oral hygiene composition
WO1999061014A3 (en) Compositions and methods employing r(-) fluoxetine and other active ingredients
EP1648531B1 (en) Use of antiseptic active principles in pmma bone cements
CA2020346A1 (en) Antibiotic ge 2270 factors a1, a2, a3 and h

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed